Loading institutional data...
Loading institutional data...
Institutional ownership roughly stable: -0.45% change quarter-over-quarter.
Data as of Q1 2026
Loading snapshot...
Loading financials...
Solve the discounted cash flow backwards, then stress-test the assumptions.
This company doesn't have positive free cash flow, so a reverse DCF can't be run.
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Total shares institutions bought (green) vs sold (red) each quarter across all holders.
Inferred from quarter-over-quarter change in each fund's 13F position (new stakes count as buys, exits as sells). Not tick-level trades.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Cash-conversion data unavailable. Lower/negative accruals = higher quality (Sloan).
Interest coverage is thin — monitor; leverage rising year-over-year.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned on -$69M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Operating income fell despite reinvestment — a warning on capital productivity. Current ROIC on all capital: -21%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Cash of $365M covers all $281M of scheduled principal — no refinancing pressure. Scheduled principal only (excludes interest & revolver draws). As of 2026-03-31 (10-K).
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Thin coverage — earnings barely cover interest. Effective rate ~17.6% on $217M of debt.
Cash of $365M fully covers short-term debt of $16M.
Mostly long-term debt (balance-sheet current vs non-current split). See the maturity ladder above for the year-by-year repayment schedule.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Maturity ladder from the SEC long-term-debt repayment schedule. Educational — not a recommendation.
EOD close · as of 2026-08-05
Where each multiple sits in its own 11-yr range · 12th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 11-yr history.
Is the profit real, and how strong is the balance sheet?
FY2026 · every deduction from revenue to net income
DuPont — the three levers
Watch the leverage lever — a chunk of ROE comes from the balance sheet.
What the company owes vs. what it holds
Year-by-year maturities aren't in SEC companyfacts (footnote-only), so this shows the debt/cash structure and net leverage instead.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 6.5× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2020 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | — | 107.9 | 87.8 | 139.4 | 119.1 | 72.8 | 70.4 | 75.5 |
| Gross Profit | — | -7.9 | 12.2 | -39.4 | -19.1 | 27.2 | 29.6 | 24.5 |
| R&D | — | 15.5 | 10.5 | 6.8 | 6.5 | 1.6 | 1.0 | 0.9 |
| SG&A | — | 174.0 | 105.3 | 87.3 | 102.8 | 77.2 | 63.1 | 56.2 |
| Operating Income | — | -418.5 | -227.5 | -214.2 | -789.3 | -77.0 | -43.5 | -56.8 |
| Income Tax | — | -30.5 | -2.4 | -1.9 | -1.7 | 4.1 | 2.7 | 0.0 |
| Net Income | -206.0 | -331.3 | -319.2 | -52.1 | -727.1 | -177.0 | -131.6 | -66.4 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on CGC: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-08-05 · 15d old
How a revenue dollar becomes profit — FY2026
Each value shows its share of revenue below it (common-size).
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $284.6M 100.0% | $269.0M 100.0% | $297.1M 100.0% | $333.3M 100.0% | $475.7M 100.0% | $546.6M 100.0% | $398.8M 100.0% | $12.8M 100.0% | $226.3M 100.0% | $77.9M 100.0% |
| Cost of Revenue | $214.9M 75.5% | $189.5M 70.4% | $216.3M 72.8% | $396.8M 119.1% | $663.1M 139.4% | $479.7M 87.8% | $430.5M 107.9% | — | $198.1M 87.5% | $45.0M 57.7% |
| Gross Profit | $69.7M 24.5% | $79.5M 29.6% | $80.9M 27.2% | -$63.5M -19.1% | -$187.4M -39.4% | $67.0M 12.2% | -$31.7M -7.9% | — | $28.2M 12.5% | $33.0M 42.3% |
| Research & Development | $2.6M 0.9% | $2.7M 1.0% | $4.6M 1.6% | $21.7M 6.5% | $32.3M 6.8% | $57.6M 10.5% | $61.8M 15.5% | — | $15.2M 6.7% | $2.1M 2.6% |
| Selling, General & Admin | $160.0M 56.2% | $169.6M 63.1% | $229.4M 77.2% | $342.5M 102.8% | $415.4M 87.3% | $575.4M 105.3% | $693.7M 174.0% | — | $392.3M 173.3% | $103.5M 132.8% |
| Total Operating Expenses | $231.3M 81.3% | $196.7M 73.1% | $309.6M 104.2% | $2.57B 770.3% | $831.4M 174.8% | $1.31B 239.7% | $1.64B 410.6% | — | $665.7M 294.1% | $152.6M 195.8% |
| Operating Income | -$161.7M -56.8% | -$117.1M -43.5% | -$228.7M -77.0% | -$2.63B -789.3% | -$1.02B -214.2% | -$1.24B -227.5% | -$1.67B -418.5% | — | -$637.5M -281.6% | -$119.6M -153.4% |
| Interest Expense | $38.2M 13.4% | $74.6M 27.7% | $105.4M 35.5% | $126.2M 37.9% | $103.9M 21.9% | $8.5M 1.5% | $6.7M 1.7% | — | $2.0M 0.9% | $784K 1.0% |
| Other Income (Expense), net | -$101.2M -35.6% | -$390.6M -145.2% | -$279.1M -93.9% | -$455.6M -136.7% | $751.0M 157.9% | -$387.9M -71.0% | $224.3M 56.3% | — | -$59.7M -26.4% | $69.6M 89.3% |
| Pretax Income | -$262.9M -92.4% | -$507.8M -188.8% | -$507.8M -170.9% | -$3.09B -926.1% | -$267.9M -56.3% | -$1.68B -308.1% | -$1.51B -378.4% | — | -$707.9M -312.8% | -$51.5M -66.0% |
| Income Tax Expense | $23K 0.0% | $7.1M 2.7% | $12.3M 4.1% | -$5.7M -1.7% | -$8.9M -1.9% | -$13.1M -2.4% | -$121.6M -30.5% | — | $4.1M 1.8% | -$392K -0.5% |
| Net Income | -$189.0M -66.4% | -$354.0M -131.6% | -$526.0M -177.0% | -$2.42B -727.1% | -$248.0M -52.1% | -$1.74B -319.2% | -$1.32B -331.3% | -$26.3M -206.0% | -$736.3M -325.3% | -$67.3M -86.3% |
| Per Share | ||||||||||
| EPS (Basic) | $-0.88 | $-4.73 | $-9.27 | $-70.69 | $-7.92 | $-4.69 | $-3.80 | — | $-2.76 | — |
| EPS (Diluted) | $-0.88 | $-4.73 | $-9.27 | $-70.69 | $-7.92 | $-4.69 | $-3.80 | — | $-2.76 | — |
| Weighted Avg Shares (Basic) | 298.0M | 107.6M | 74.8M | 46.4M | 39.1M | 371.7M | — | — | — | — |
| Weighted Avg Shares (Diluted) | 298.0M | 107.6M | 74.8M | 46.4M | 39.1M | 371.7M | — | — | — | — |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Ranked against 1111 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-03-31.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.05T | 51.0× | — | 16.1× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,193 |
| AKTX | $679.0B | — | — | — | — | — | — | -61.1% | -61.1% | — | 1 |
| JNJ | $620.1B | 23.4× | — | 6.6× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | — | 4,451 |
| ABBV | $435.4B | 104.3× | 31.4× | 7.1× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 4.2× | 3,895 |
| UNH | $374.0B | 31.2× | 21.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 3.9× | 2,891 |
| BDRX | $359.1B | — | — | — | — | — | — | — | — | — | 7 |
| MRK | $321.1B | 17.6× | — | 4.9× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,594 |
| NVSEF | $289.9B | — | — | — | — | — | — | — | — | — | 2 |
| AZN | $250.4B | — | — | — | — | — | — | — | — | — | 1,248 |
| AMGN | $219.7B | 28.7× | 18.3× | 6.0× | 10.0% | 67.2% | 21.0% | 89.1% | 13.1% | 3.5× | 3,014 |
| TMO | $217.8B | 32.6× | 28.5× | 4.9× | 3.9% | — | 15.1% | 12.6% | 7.0% | 4.9× | 2,481 |
| ABT | $183.9B | 28.4× | 19.5× | 4.2× | 5.7% | 56.4% | 14.7% | 12.5% | 10.5% | 1.0× | 2,964 |
| GILD | $163.5B | 19.4× | 18.1× | 5.5× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,218 |
| PFE | $146.7B | 19.0× | — | 2.3× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,838 |
| DHR | $141.1B | 39.5× | 29.3× | 5.7× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,083 |
| ISRG | $133.2B | 47.7× | 36.6× | 13.2× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | — | 2,190 |
| SYK | $128.8B | 40.1× | 21.8× | 5.1× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 2.5× | 2,196 |
| CVS | $126.0B | 71.3× | 12.7× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | 0.0× | 1,795 |
| VRTX | $123.1B | 31.6× | 26.9× | 10.3× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | — | 1,609 |
| MDT | $110.1B | 23.1× | 11.7× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 9.4% | 0.2× | 2,114 |
| GLAXF | $106.9B | — | — | — | — | — | — | — | — | — | 5 |
| MCK | $102.7B | 22.9× | 16.2× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 1.0× | 1,946 |
| SNYNF | $101.3B | — | — | — | — | — | — | — | — | — | 5 |
| HCA | $92.0B | 14.5× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,346 |
| ELV | $86.4B | 15.5× | 14.8× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 4.2× | 1,397 |
| CGC | $393M | — | — | 1.4× | 5.8% | 24.5% | -66.4% | -27.1% | -20.7% | -1.5× | 5 |
Peers = companies sharing CGC's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Top 6 institutional holders — bubble size is position value, color is the move since last quarter. Hover any holder for detail.
Drag any bubble to rearrange · size = dollar value of the position